Vanguard Group Inc Black Diamond Therapeutics, Inc. Call Options Transaction History
Vanguard Group Inc
- $4.96 Trillion
- Q1 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding BDTX
# of Institutions
93Shares Held
36.5MCall Options Held
29.6KPut Options Held
5K-
Bellevue Group Ag Kuesnacht, V88.52MShares$37.8 Million0.68% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD6.73MShares$29.9 Million0.02% of portfolio
-
Nea Management Company, LLC Timonium, MD4.45MShares$19.8 Million1.58% of portfolio
-
Tang Capital Management LLC San Diego, CA1.6MShares$7.12 Million0.99% of portfolio
-
Black Rock Inc. New York, NY1.38MShares$6.13 Million0.0% of portfolio
About Black Diamond Therapeutics, Inc.
- Ticker BDTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,339,500
- Market Cap $161M
- Description
- Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epide...